Rituximab for Pediatric Renal Transplant Rejection

Completed · Phase 2/Phase 3

Conditions studied: Kidney Transplantation

In brief

Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University

Key facts

Study ID

NCT00697996

Run by

Stanford University

People needed

20

Starts

2005-06-01

Expected to finish

2007-08-01

Last updated by the study team

2008-12-23

Who can join

Age: 5 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.